Alvotech
ALVO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001898416
No open-market purchases or sales by Alvotech insiders were filed in the last 90 days; 72 institutions reported holding it in 13F filings for Q2 2026, worth $157.4M in total; Oaktree Capital is the only superinvestor holding it.
Other share classesALVOW
Q3 2024 vs. Q2 2024
How the institutions holding Alvotech changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 31 | 32 | +1 |
| Shares | 14.5M | 15.2M | +669.4K (+4.6%) |
| Value | $174.0M | $178.2M | +$4.26M (+2.5%) |
New holders (5)
Institutions that held Alvotech at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Farallon Capital Management, L.L.C. | 199,675 | $2.38M | 0.01% |
| ExodusPoint Capital Management, LP | 34,111 | $406.0K | 0.00% |
| Citadel Advisors LLC | 21,249 | $252.9K | 0.00% |
| FreeGulliver LLC | 43,681 | $118.4K | 0.07% |
| Wolverine Asset Management LLC | 5,841 | $69.5K | 0.00% |
Sold out (4)
Institutions that held Alvotech at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Balyasny Asset Management LLC | 848,444 | $10.3M |
| Goldman Sachs Group Inc | 11,656 | $141.7K |
| Quarry LP | 1,184 | $14.4K |
| Royal Bank of Canada | 9 | $0 |